US Urothelial Carcinoma Market Size, Share, Impressive Industry Growth, Analysis Report 2028

The US urothelial carcinoma market is estimated to grow modestly at a CAGR of around 9.6% during the forecast period. The US contributes significantly to the growth of the urothelial carcinoma treatment market in North America. The healthcare spending of the US is significantly high as compared to that of other regions. The US spends almost 17.2% of GDP on healthcare expenditure in 2018. Moreover, the investments in R&D and a surging pool of geriatric population coupled with a high prevalence of urothelial carcinoma is driving the market growth in the US. US Census Bureau estimated that people aged over 65 years represent around 15% of the total population of the country in 2015. This share is further estimated to reach 21% by 2030 and 24% by 2060. Moreover, the US has the presence of some of the key players operating in the urothelial carcinoma market such as Merck & Co, Inc., Pfizer, Inc., and Spectrum Pharmaceuticals, Inc., which further augments the growth of the market in the country.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-urothelial-carcinoma-market

US urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most commonly used method in the diagnosis and treatment of urothelial carcinoma. The cystoscopy uses special tools that may be passed through cystoscope to treat very small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.

The companies which are contributing to the growth of the US urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

US Urothelial Carcinoma Market- Segmentation

By Diagnosis

• Cystoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Intravenous Pyelogram (IVP)
• Others (Biomarkers)

By Treatment

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others (Targeted Therapy)

A full report of US Urothelial Carcinoma Market is available at: https://www.omrglobal.com/industry-reports/us-urothelial-carcinoma-market

Company Profiles

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• EMD Serono, Inc.
• F. Hoffmann-La Roche Ltd.
• Genentech Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Spectrum Pharmaceuticals, Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.